News

DENVER – Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. Collectively, these findings illustrate the potential and reach of liquid biopsies in both identifying patients suitable for targeted treatment as well as predicting cancer recurrence.

DENVER – Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.

July 2016 Newsletter

With the recent announcement that a first-line immunotherapy trial for non-small cell lung cancer (NSCLC) is positive for survival improvement, I can see the standard of care for lung cancer patients radically changing over the next few years.

BETHESDA, MD. — June 28, 2016 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.”

DENVER – The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3.1 – 7 cm.

DENVER – The International Association for the Study of Lung Cancer (IASLC) praises the U.S. Food and Drug Administration’s (FDA) decision to approve the first blood test to detect an oncogenic driver mutation in non-small cell lung cancer (NSCLC). This marks a significant step forward in lung cancer treatment. The cobas EGFR Mutation Test v2 detects epidermal growth factor receptor (EGFR) gene mutations and the FDA approved. It is a blood-based companion diagnostic for the EGFR tyrosine kinase inhibitor erlotinib (Tarceva).

Pages